Quantbot Technologies LP Sells 7,499 Shares of Halozyme Therapeutics, Inc. $HALO

Quantbot Technologies LP lowered its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 47.2% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 8,373 shares of the biopharmaceutical company’s stock after selling 7,499 shares during the period. Quantbot Technologies LP’s holdings in Halozyme Therapeutics were worth $614,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. CWM LLC grew its holdings in shares of Halozyme Therapeutics by 2,136.0% in the third quarter. CWM LLC now owns 23,881 shares of the biopharmaceutical company’s stock valued at $1,751,000 after purchasing an additional 22,813 shares in the last quarter. Arbor Investment Advisors LLC purchased a new position in shares of Halozyme Therapeutics during the third quarter worth approximately $1,316,000. Monument Capital Management purchased a new position in shares of Halozyme Therapeutics during the third quarter valued at $2,015,000. Pacer Advisors Inc. boosted its stake in shares of Halozyme Therapeutics by 2,054.7% during the third quarter. Pacer Advisors Inc. now owns 478,874 shares of the biopharmaceutical company’s stock valued at $35,121,000 after purchasing an additional 456,649 shares in the last quarter. Finally, Cardinal Capital Management bought a new stake in Halozyme Therapeutics during the third quarter valued at about $1,303,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on HALO. Benchmark boosted their price target on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, January 29th. Weiss Ratings cut shares of Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research note on Tuesday, February 24th. TD Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Finally, Wall Street Zen downgraded Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Saturday, February 21st. Six investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $78.56.

Halozyme Therapeutics Stock Up 0.0%

Shares of NASDAQ HALO opened at $67.37 on Monday. The business’s fifty day simple moving average is $72.66 and its 200-day simple moving average is $70.72. The company has a current ratio of 4.66, a quick ratio of 3.66 and a debt-to-equity ratio of 43.89. The stock has a market cap of $7.95 billion, a P/E ratio of 27.06, a PEG ratio of 0.27 and a beta of 0.98. Halozyme Therapeutics, Inc. has a 12-month low of $47.50 and a 12-month high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of $1.92 by ($2.16). Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The company had revenue of $451.77 million for the quarter, compared to analyst estimates of $446.13 million. During the same period in the prior year, the firm posted $1.26 earnings per share. The business’s quarterly revenue was up 51.6% compared to the same quarter last year. As a group, equities analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Insider Activity

In other news, Director Bernadette Connaughton sold 2,000 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $70.25, for a total value of $140,500.00. Following the completion of the transaction, the director owned 40,123 shares in the company, valued at approximately $2,818,640.75. This represents a 4.75% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $76.12, for a total value of $1,522,400.00. Following the transaction, the chief executive officer directly owned 708,719 shares in the company, valued at approximately $53,947,690.28. The trade was a 2.74% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 62,000 shares of company stock valued at $4,545,200. Insiders own 2.90% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.